Literature DB >> 24589084

Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.

O Stasyshyn1, S Antunes, V Mamonov, X Ye, J Epstein, Y Xiong, S Tangada.   

Abstract

The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Factor Eight Inhibitor Bypassing Activity (FEIBA) prophylaxis. This study investigates whether 12-month of FEIBA prophylaxis improved HRQoL in haemophilia patients with inhibitors. Thirty-six subjects in a 1-year prospective, randomized, open-label, parallel-design study were randomized to prophylaxis (85 ± 15 U kg(-1) every other day) or on-demand treatment. HRQoL was assessed at screening, 6 and 12-month termination using the EQ-5D, Haem-A-QoL, Haemo-QoL and a general pain visual analog scale (VAS). To evaluate changes, paired t-tests and criteria for minimally important differences were applied. Repeated measures regression tested the association between annualized bleeding rate (ABR) and physical HRQoL. At 6 and 12 months, prophylaxis subjects reported clinically meaningful improvement in EQ-5D index (mean improvement, 0.10 and 0.08, respectively) and both clinically meaningful and statistically significant improvements in EQ-VAS scores (16.9 and 15.7, respectively; P < 0.05) vs. baseline. General pain was significantly reduced during prophylaxis at each follow-up (mean improvement, 20.3 and 23.2, respectively; both P <0.05). At 12 months, prophylaxis subjects achieved significant improvements in Haem-A-QoL Total Score and in four domains: Physical Health, Feeling, View, and Work and School (all P < 0.05). No statistically significant changes, except for Haem-A-QoL Physical Health at 6 months, were observed with on-demand treatment. ABR was decreased by 72.5% with prophylaxis vs. on-demand treatment (P = 0.0003) and reduced ABR was associated with better physical HRQoL (P < 0.05). FEIBA prophylaxis significantly reduced ABR and improved HRQoL in inhibitor patients. Subjects with lower ABR reported better physical HRQoL.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  anti-inhibitor coagulant complex; factor eight inhibitor bypassing activity; haemophilia; health-related quality of life; prophylaxis

Mesh:

Substances:

Year:  2014        PMID: 24589084     DOI: 10.1111/hae.12390

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

Review 1.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

Review 2.  Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.

Authors:  Chatree Chai-Adisaksopha; Sarah J Nevitt; Mindy L Simpson; Maissaa Janbain; Barbara A Konkle
Journal:  Cochrane Database Syst Rev       Date:  2017-09-25

Review 3.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

4.  Inhibitor clinical burden of disease: a comparative analysis of the CHESS data.

Authors:  Abiola O Oladapo; Mei Lu; Shaun Walsh; Jamie O'Hara; Teresa L Kauf
Journal:  Orphanet J Rare Dis       Date:  2018-11-09       Impact factor: 4.123

5.  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Authors:  Johnny Mahlangu; Johannes Oldenburg; Michael U Callaghan; Midori Shima; Maria Elisa Mancuso; Peter Trask; Michael Recht; Claudia Garcia; Renchi Yang; Michaela Lehle; Harrison Macharia; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres; Sylvia von Mackensen
Journal:  Haemophilia       Date:  2019-04-24       Impact factor: 4.287

6.  Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Authors:  Karissa Johnston; Jayson M Stoffman; Alexis T Mickle; Robert J Klaassen; Demitri Diles; Shade Olatunde; Lina Eliasson; Roxana Bahar
Journal:  Patient Prefer Adherence       Date:  2021-06-24       Impact factor: 2.711

7.  Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial.

Authors:  Valerie A Sera; Ann E Stevens; Howard K Song; Victor M Rodriguez; Frederick A Tibayan; Miriam M Treggiari
Journal:  Pilot Feasibility Stud       Date:  2021-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.